

Special Issue

Molecular Advances in Drug Resistance and Novel Therapies for Cancer

Message from the Guest Editors

Cancer drug discovery has immensely advanced since its earliest steps. Nevertheless, rare occurrences of anti-cancer-drug-resistant cancers show a poor prognosis via recurrence or metastasis, and these consequences can be associated with patient death. Various studies have shown that recurrent or metastatic cancer is refractory to most medical treatments. These refractory cancers are usually slow; however, following anaplasia of the injury, they are altered into poorly differentiated and undifferentiated cancer, described by a sharp expansion involving a poor prognosis. The stemness and aggressiveness of refractory cancer have not yet been revealed. Anti-cancer drug resistance remains a fundamental challenge in the treatment of patients with refractory cancer. The goal of the enclosed Special Issue is to collect the latest findings on a broad range of research including basic research in vitro, preclinical models involving substances potentially used as breakthrough clinical solutions for drug-resistant tumors, and newly introduced compounds targeting cancer therapy.

Guest Editors

Dr. Agnieszka Wolnicka-Glubisz

Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland

Dr. Konrad Kleszczyński

Department of Dermatology, University of Münster, 48149 Münster, Germany

Deadline for manuscript submissions

31 March 2026



Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



mdpi.com/si/217481

Biomolecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)





Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)